Table 2.
Characteristics and outcomes of eight patients who received cyclosporine in the 2009–2017 group.
| Patient | Age at diagnosis (year) | Sex | Autoimmune disease | Time from diagnosis to CsA therapy | Time to PR after CsA therapy (day) | Time to CR after CsA therapy (day) | Additional IVIG (CsA level (ng/mL)) | PSL after CsA therapy | Relapse after CR | Therapy for relapse | Duration of CsA therapy | Status at 3 years after diagnosis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | F | (―) | 2 months | 10 | 14 | (―) | (―) | 1 month | CsA dose adjustment | 25 months | CR |
| 2 | 2 | F | (―) | 10 months | 13 | 119 | (―) | (―) | (―) | (―) | 20 months | CR |
| 3 | 11 | M | (―) | 24 days | 36 | 38 | day 34 (183) | (―) | (―) | (―) | 19 months | CR |
| 4 | 1 | F | (―) | 1 month | 20 | 20 | day 18 (132) | (―) | 9 months | CsA dose adjustmentAdditional IVIG | 24 months | CR |
| 5 | 2 | M | (―) | 14 days | 19 | 22 |
day 9 (145) day 16 (147) |
(―) | (―) | (―) | 5 months | CR |
| 6 | 9 | F | Sjogren's syndrome | 5 months | 15 | (―) | (―) | day 106- | (―) | (―) | 32 + months | PR |
| 7 | 1 | M | (―) | 1 month | 13 | 13 | day 10 (100) | (―) | 2 months | CsA dose adjustment | 5 months | CR |
| 8 | 6 | M | (―) | 1 month | (―) | (―) | (―) | (―) | (―) | (―) | 14 months | NR |
CR, complete response; CsA, cyclosporine; IVIG, intravenous immunoglobulin; NR, no response; PR, partial response; PSL, prednisolone.